These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 22310929)

  • 1. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice.
    Triozzi PL; Aldrich W; Achberger S; Ponnazhagan S; Alcazar O; Saunthararajah Y
    Cancer Immunol Immunother; 2012 Sep; 61(9):1441-50. PubMed ID: 22310929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists.
    Triozzi PL; Aldrich W; Ponnazhagan S
    Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
    Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
    Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine.
    Daurkin I; Eruslanov E; Vieweg J; Kusmartsev S
    Cancer Immunol Immunother; 2010 May; 59(5):697-706. PubMed ID: 19882154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrains its agonist-based immunotherapy.
    Kortylewski M; Kujawski M; Herrmann A; Yang C; Wang L; Liu Y; Salcedo R; Yu H
    Cancer Res; 2009 Mar; 69(6):2497-505. PubMed ID: 19258507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
    Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
    Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.
    Mattei F; Schiavoni G; Sestili P; Spadaro F; Fragale A; Sistigu A; Lucarini V; Spada M; Sanchez M; Scala S; Battistini A; Belardelli F; Gabriele L
    Neoplasia; 2012 Dec; 14(12):1223-35. PubMed ID: 23308054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with interleukin-2/interferon-gamma double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma.
    Kim TS; Xu WS; Sun T; Cohen EP
    Melanoma Res; 1995 Aug; 5(4):217-27. PubMed ID: 7496156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of interleukin-1 receptor antagonist and chemotherapy on host-tumor interactions in established melanoma.
    Triozzi PL; Aldrich W
    Anticancer Res; 2010 Feb; 30(2):345-54. PubMed ID: 20332438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells.
    Zhou J; Yao Y; Shen Q; Li G; Hu L; Zhang X
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1371-1380. PubMed ID: 28321548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.
    Du HY; Dong LH; Zhao BJ; Fu J; Wang QQ; Chen F; Ou L; Li N; Sun X; Tang ZM; Song HF
    Acta Pharmacol Sin; 2012 Aug; 33(8):1047-54. PubMed ID: 22728711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with an immature dendritic cell-targeting vaccine supplemented with IFN-α and an inhibitor of DNA methylation markedly enhances survival in a murine melanoma model.
    Gordy JT; Luo K; Kapoor A; Kim ES; Ayeh SK; Karakousis PC; Markham RB
    Cancer Immunol Immunother; 2020 Apr; 69(4):569-580. PubMed ID: 31980915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antitumor immunity and treatment of preestablished tumor by interleukin-6-gene-transfected melanoma cells combined with low-dose interleukin-2.
    Cao X; Zhang W; Gu S; Yu Y; Tao Q; Ye T
    J Cancer Res Clin Oncol; 1995; 121(12):721-8. PubMed ID: 7499443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Co-delivery of tumor antigen and dual toll-like receptor ligands into dendritic cell by silicon microparticle enables efficient immunotherapy against melanoma.
    Zhu M; Ding X; Zhao R; Liu X; Shen H; Cai C; Ferrari M; Wang HY; Wang RF
    J Control Release; 2018 Feb; 272():72-82. PubMed ID: 29325699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
    Klebanoff CA; Gattinoni L; Palmer DC; Muranski P; Ji Y; Hinrichs CS; Borman ZA; Kerkar SP; Scott CD; Finkelstein SE; Rosenberg SA; Restifo NP
    Clin Cancer Res; 2011 Aug; 17(16):5343-52. PubMed ID: 21737507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.